Navigation Links
Research and Markets: Personalized Medicine - Scientific and Commercial Aspects - 2013 Report

Dublin, Ireland (PRWEB) March 08, 2013

Research and Markets has announced the addition of Jain PharmaBiotech's new report "Personalized Medicine - Scientific and Commercial Aspects" to their offering.

The aim of this personalized medicine market research report or individualized treatment is to match the right drug to the right patient and, in some cases, even to design the appropriate treatment for a patient according to his/her genotype. This report describes the latest concepts of development of personalized medicine based on pharmacogenomics, pharmacogenetics,pharmacoproteomics, and metabolomics. Basic technologies of molecular diagnostics play an important role, particularly those for single nucleotide polymorphism (SNP) genotyping. Diagnosis is integrated with therapy for selection of the treatment as well for monitoring the results. Biochip/microarray technologies are also important and finally bioinformatics is needed to analyze the immense amount of data generated by various technologies.

Pharmacogenetics, the study of influence of genetic factors on drug action and metabolism, is used for predicting adverse reactions of drugs. Several enzymes are involved in drug metabolism of which the most important ones are those belonging to the family of cytochrome P450. The knowledge of the effects of polymorphisms of genes for the enzymes is applied in drug discovery and development as well as in clinical use of drugs. Cost-effective methods for genotyping are being developed and it would be desirable to include this information in the patient's record for the guidance of the physician to individualize the treatment. Pharmacogenomics, a term that overlaps with pharmacogenetics but is distinct, deals with the application of genomics to drug discovery and development. It involves the mechanism of action of drugs on cells as revealed by gene expression patterns. Pharmacoproteomics is an important contribution to personalized medicine as it is a more functional representation of patient-to-patient variation than that provided by genotyping. A 'pharmacometabonomic' approach to personalizing drug treatment is also described.

Biological therapies such as those which use patient's own cells are considered to be personalized medicines. Vaccines are prepared from individual patient's tumor cells. Individualized therapeutic strategies using monoclonal bodies can be directed at specific genetic and immunologic targets. Ex vivo gene therapy involves the genetic modification of the patient's cells in vitro, prior to reimplantation of these cells in the patient's body.

Various technologies are integrated to develop personalized therapies for specific therapeutic areas described in the report. Examples of this are genotyping for drug resistance in HIV infection, personalized therapy of cancer, antipsychotics for schizophrenia, antidepressant therapy, antihypertensive therapy and personalized approach to neurological disorders. Although genotyping is not yet a part of clinically accepted routine, it is expected to have this status by the year 2016.

Increase in efficacy and safety of treatment by individualizing it has benefits in financial terms. Information is presented to show that personalized medicine will be cost-effective in healthcare systems. For the pharmaceutical companies, segmentation of the market may not leave room for conventional blockbusters but smaller and exclusive markets for personalized medicines would be profitable. Marketing opportunities for such a system are described with market estimates from 2011-2021.

Profiles of 279 companies involved in developing technologies for personalized medicines, along with 500 collaborations are included in the part II of the report. Finally the bibliography contains over 650 selected publications cited in the report.The report is supplemented by 65 tables and 18 figures.

Key Topics Covered:

Part I: Scientific & Commercial Aspects

1. Basic Aspects

2. Molecular Diagnostics in Personalized Medicine

3. Pharmacogenetics

4. Pharmacogenomics

5. Role of Pharmacoproteomics

6. Role of Metabolomics in Personalized Medicine

7. Personalized Biological Therapies

8. Personalized Medicine in Major Therapeutic Areas

9. Personalized Therapy of Cancer

10. Development of Personalized Medicine

11. Ethical and Regulatory Aspects of Personalized Medicine

12. Commercial Aspects of Personalized Medicine

13. References

Part II: Companies

14. Companies Involved in Developing Personalized Medicine

For more information visit

Source: Jain PharmaBiotech

Research and Markets
Laura Wood, Senior Manager.
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Wolters Kluwer Research Now Available via Bloomberg Tradebook
2. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
3. New England Biolabs Introduces Polbase, an Information Repository of Scientific Data for Polymerase Researchers
4. Researching graphene nanoelectronics for a post-silicon world
5. In new quantum-dot LED design, researchers turn troublesome molecules to their advantage
6. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
7. New research points to benefits of innovative cobas® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
8. Multidisciplinary team of researchers develop world’s lightest material
9. K computer research results awarded ACM Gordon Bell Prize
10. ResearchMoz: Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market
11. Researchers shrink tumors and minimize side effects using tumor-homing peptide to deliver treatment
Post Your Comments:
(Date:12/1/2015)... SAN FRANCISCO , Dec. 1, 2015  Symic, ... and affect the extracellular matrix (ECM), today announced that ... financing to advance the company,s pipeline, including its lead ... Lilly Ventures and includes the participation by all existing ... new funding brings the total capital raised by Symic ...
(Date:12/1/2015)... Texas (PRWEB) , ... December 01, 2015 , ... Matthew ... his new post, VerMilyea will oversee all IVF lab procedures as well ... and fertility preservation. , “We traveled 7,305 miles to Auckland, New Zealand to bring ...
(Date:11/30/2015)... ... 2015 , ... Global Stem Cells Group today ... Santiago Marriott. The Global Stem Cells Group GMP facility is equipped with the ... medical researchers and practitioners, experienced in administering stem cell protocols using highly manipulated ...
(Date:11/30/2015)... 1, 2015 Partnership includes an ... for the u niversity , s ... treatment s cale - up ... Africa , where licensees based anywhere in the world will ... technology. --> Africa , where licensees based anywhere in the ...
Breaking Biology Technology:
(Date:10/29/2015)... Connecticut , October 29, 2015 ... a biometric authentication company focused on the growing ... smart wallet announces that StackCommerce, a leading marketplace ... be featuring the Wocket® smart wallet on StackSocial ... NXTD ) ("NXT-ID" or the "Company"), a biometric ...
(Date:10/27/2015)... 27, 2015 In the present market scenario, ... for various industry verticals such as banking, healthcare, defense, ... growing demand for secure & simplified access control and ... as hacking of bank accounts, misuse of users, , ... as PC,s, laptops, and smartphones are expected to provide ...
(Date:10/27/2015)... SAN JOSE, Calif. , Oct. 27, 2015 /PRNewswire/ ... human interface solutions, today announced that Google has adopted ... family of touch controller solutions to power its newest ... Nexus 6P by Huawei. --> ... ecosystem partners like Google to provide strategic collaboration in ...
Breaking Biology News(10 mins):